ADD LIFE. Don't wait to prescribe VETMEDIN to see the difference it can make for dogs with CHF. VETMEDIN is recommended by the ACVIM as part of standard treatment for dogs with CHF. 1 Well-known clinical studies have established that VETMEDIN can help dogs with CHF feel better and live longer. 2,3 The QUEST study update showed that dogs treated with VETMEDIN required less therapy to maintain quality of life (QOL) than those treated with an ACE inhibitor. 4 DOSING SIZES Now available in 4 BECAUSE EVERYONE DESERVES MORE MOMENTS LIKE THIS.
References: 1. Atkins C, Bonagura J, Ettinger S, et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med. 2009;23(6):1142–1150. 2. Häggström J, Boswood A, O’Grady M, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QuESt study. J Vet Intern Med. 2008;22(5):1124–1135. 3. Lombard CW, Jöns O, Bussadori CM; for the VetSCOPE Study. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc. 2006;42(4):249–261. 4. Häggström J, Boswood A, O’Grady M, et al. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QuESt study. J Vet Intern Med. 2013;27(6):1441–1451.
ADD LIFE.
Don't wait to prescribe VETMEDIN to see the difference it can make for dogs with CHF.
VEtMEDIN is recommended by the ACVIM as part of standard treatment for dogs with CHF.1
Well-known clinical studies have established that VEtMEDIN can help dogs with CHF feel better and live longer.2,3
the QuESt study update showed that dogs treated with VEtMEDIN required less therapy to maintain quality of life (QOL) than those treated with an ACE inhibitor.4
Important safety information: the safe use of VEtMEDIN has not been evaluated in dogs younger than 6 months of age, dogs with congenital heart defects, dogs with diabetes mellitus or other serious metabolic diseases, dogs used for breeding, or pregnant or lactating bitches. use only in dogs with clinical evidence of heart failure. For additional information, see the full prescribing information enclosed.
Important safety information: VEtMEDIN should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. the safety of VEtMEDIN has not been established in dogs with asymptomatic heart disease or in heart failure caused by etiologies other than atrioventricular valvular insufficiency or dilated cardiomyopathy. use only in dogs with clinical evidence of heart failure. the most common side effects reported in field studies were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. If side effects should occur, pet owners should contact their veterinarian.
VEtMEDIN is available for your client’s convenience in 1.25 mg, 2.5 mg, 5 mg, and 10 mg dosage sizes. these additional dosing options will:
Help you ensure accurate dosing
Encourage ongoing compliance
Give owners choices that are both effective and cost-effective
Think VETMEDIN from the start and make it the heart of your treatment plan.
For more information, contact your Boehringer Ingelheim sales representative or visit www.vetmedin.com.
don’t wait. Use VetMedin froM the start to help dogs with Chf liVe longer.2
for dogs of any size or shape, Use VetMedin at the first CliniCal signs of Chf.
VETMEDIN is recommended for use at the onset of clinical signs of CHF.1
VETMEDIN improves QOL and helps dogs with CHF feel better.3
VETMEDIN is now available in 4 dosage sizes to fit each dog's individual needs.
VETMEDIN is proven to lengthen life with few adverse events.2
Use VetMedin here
stage aHigh-risk dogs with
no structural abnormality or murmur
stage BStructural abnormality but
no clinical signs of heart failure
stage dClinical signs of heart
failure refractory to standard treatment
stage CStructural abnormality
and current or previous clinical signs
of heart failure
presCriBing inforMation enClosed
* Both the QuESt and VetSCOPE studies were completed using VEtMEDIN Capsules. In the uS, only the chewable tablets are licensed. Both the capsules and chewable tablets contain the same pharmaceutical ingredient, pimobendan, and are considered equivalent for clinical use. Bioequivalence, however, has not been shown.
† Survival was defined as the composite endpoint of cardiac death, euthanasia due to heart failure, or treatment failure. All dogs received furosemide therapy.
§ All doses provided as tablets.
dosing sizes
Now available in
4
Simon, 12O lbTwo 10 mg in morning andone 10 mg in evening§Clyde, 65 lb
10 mg in morning and half a 10 mg in evening§Lucky, 22 lb
References: 1. Atkins C, Bonagura J, Ettinger S, et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med. 2009;23(6):1142–1150. 2. Häggström J, Boswood A, O’Grady M, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QuESt study. J Vet Intern Med. 2008;22(5):1124–1135. 3. Lombard CW, Jöns O, Bussadori CM; for the VetSCOPE Study. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc. 2006;42(4):249–261. 4. Häggström J, Boswood A, O’Grady M, et al. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QuESt study. J Vet Intern Med. 2013;27(6):1441–1451.
ADD LIFE.
Don't wait to prescribe VETMEDIN to see the difference it can make for dogs with CHF.
VEtMEDIN is recommended by the ACVIM as part of standard treatment for dogs with CHF.1
Well-known clinical studies have established that VEtMEDIN can help dogs with CHF feel better and live longer.2,3
the QuESt study update showed that dogs treated with VEtMEDIN required less therapy to maintain quality of life (QOL) than those treated with an ACE inhibitor.4
Important safety information: the safe use of VEtMEDIN has not been evaluated in dogs younger than 6 months of age, dogs with congenital heart defects, dogs with diabetes mellitus or other serious metabolic diseases, dogs used for breeding, or pregnant or lactating bitches. use only in dogs with clinical evidence of heart failure. For additional information, see the full prescribing information enclosed.
Important safety information: VEtMEDIN should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. the safety of VEtMEDIN has not been established in dogs with asymptomatic heart disease or in heart failure caused by etiologies other than atrioventricular valvular insufficiency or dilated cardiomyopathy. use only in dogs with clinical evidence of heart failure. the most common side effects reported in field studies were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. If side effects should occur, pet owners should contact their veterinarian.
VEtMEDIN is available for your client’s convenience in 1.25 mg, 2.5 mg, 5 mg, and 10 mg dosage sizes. these additional dosing options will:
Help you ensure accurate dosing
Encourage ongoing compliance
Give owners choices that are both effective and cost-effective
Think VETMEDIN from the start and make it the heart of your treatment plan.
For more information, contact your Boehringer Ingelheim sales representative or visit www.vetmedin.com.
don’t wait. Use VetMedin froM the start to help dogs with Chf liVe longer.2
for dogs of any size or shape, Use VetMedin at the first CliniCal signs of Chf.
VETMEDIN is recommended for use at the onset of clinical signs of CHF.1
VETMEDIN improves QOL and helps dogs with CHF feel better.3
VETMEDIN is now available in 4 dosage sizes to fit each dog's individual needs.
VETMEDIN is proven to lengthen life with few adverse events.2
Use VetMedin here
stage aHigh-risk dogs with
no structural abnormality or murmur
stage BStructural abnormality but
no clinical signs of heart failure
stage dClinical signs of heart
failure refractory to standard treatment
stage CStructural abnormality
and current or previous clinical signs
of heart failure
presCriBing inforMation enClosed
* Both the QuESt and VetSCOPE studies were completed using VEtMEDIN Capsules. In the uS, only the chewable tablets are licensed. Both the capsules and chewable tablets contain the same pharmaceutical ingredient, pimobendan, and are considered equivalent for clinical use. Bioequivalence, however, has not been shown.
† Survival was defined as the composite endpoint of cardiac death, euthanasia due to heart failure, or treatment failure. All dogs received furosemide therapy.
§ All doses provided as tablets.
dosing sizes
Now available in
4
Simon, 12O lbTwo 10 mg in morning andone 10 mg in evening§Clyde, 65 lb
10 mg in morning and half a 10 mg in evening§Lucky, 22 lb
267 days compared with 140 days on an ACE inhibitor (P=0.0099)
91%in VETMEDIN-treated dogslonger sUrViVal† tiMe
after 8 weeks compared with 29% on an ACE inhibitor (P=0.0011)
were free of signsof VETMEDIN-treated dogs74%
ACVIM guidelines
BeCaUse eVeryone deserVes More MoMents like this.
(FOLD & GLUE TO CREATE POCKET)
(FO
LD &
GLU
E T
O C
RE
ATE
PO
CK
ET)
aCt now. treat Chf with VetMedin and preserVe Qol with less therapy.4
QUEST study update: Dogs on VETMEDIN required less therapy to maintain QOL than dogs on an ACE inhibitor.4
In contrast to VetSCOPE, which measured changes in QOL, the QuESt study focused on extending survival time so intensification of therapy was permitted.2,3‡
VEtMEDIN also improved body temperature, serum sodium concentration, total protein concentration, and packed cell volume, while reducing fluid retention.4
Please refer to the package insert enclosed.
VETMEDIN-treated dogs had significantly longer time to intensification of therapy4
1.69 times more likely to intensify treatment first (P=0.0008)
VetMedin
Med
ian
in d
ays
(in
terq
uart
ile r
ang
e)
aCe inhiBitor
98(30–276) 59
(11–121)
P=0.0005
QUEST study update: VETMEDIN demonstrated a variety of clinical advantages.
VetMedin deCreased aCe inhiBitor inCreased
P=0.01312.5 baseline 12.4 after treatment 12.5 baseline 12.9 after treatment
VETMEDIN-treated dogs had less cardiac enlargement after therapy as demonstrated by significantly lower median vertebral heart score4
In dogs that were NOT given VETMEDIN, heart size continued to enlarge further beyond normal range.
Dogs that were NOT given VETMEDIN required more frequent administration of additional medications to maintain a similar QOL.
‡ Intensification of therapy was defined as an increase in the dose of benazepril or addition of concomitant treatment for either drug.4
References: 1. Atkins C, Bonagura J, Ettinger S, et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med. 2009;23(6):1142–1150. 2. Häggström J, Boswood A, O’Grady M, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QuESt study. J Vet Intern Med. 2008;22(5):1124–1135. 3. Lombard CW, Jöns O, Bussadori CM; for the VetSCOPE Study. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc. 2006;42(4):249–261. 4. Häggström J, Boswood A, O’Grady M, et al. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QuESt study. J Vet Intern Med. 2013;27(6):1441–1451.
ADD LIFE.
Don't wait to prescribe VETMEDIN to see the difference it can make for dogs with CHF.
VEtMEDIN is recommended by the ACVIM as part of standard treatment for dogs with CHF.1
Well-known clinical studies have established that VEtMEDIN can help dogs with CHF feel better and live longer.2,3
the QuESt study update showed that dogs treated with VEtMEDIN required less therapy to maintain quality of life (QOL) than those treated with an ACE inhibitor.4
Important safety information: the safe use of VEtMEDIN has not been evaluated in dogs younger than 6 months of age, dogs with congenital heart defects, dogs with diabetes mellitus or other serious metabolic diseases, dogs used for breeding, or pregnant or lactating bitches. use only in dogs with clinical evidence of heart failure. For additional information, see the full prescribing information enclosed.
Important safety information: VEtMEDIN should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. the safety of VEtMEDIN has not been established in dogs with asymptomatic heart disease or in heart failure caused by etiologies other than atrioventricular valvular insufficiency or dilated cardiomyopathy. use only in dogs with clinical evidence of heart failure. the most common side effects reported in field studies were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. If side effects should occur, pet owners should contact their veterinarian.
VEtMEDIN is available for your client’s convenience in 1.25 mg, 2.5 mg, 5 mg, and 10 mg dosage sizes. these additional dosing options will:
Help you ensure accurate dosing
Encourage ongoing compliance
Give owners choices that are both effective and cost-effective
Think VETMEDIN from the start and make it the heart of your treatment plan.
For more information, contact your Boehringer Ingelheim sales representative or visit www.vetmedin.com.
don’t wait. Use VetMedin froM the start to help dogs with Chf liVe longer.2
for dogs of any size or shape, Use VetMedin at the first CliniCal signs of Chf.
VETMEDIN is recommended for use at the onset of clinical signs of CHF.1
VETMEDIN improves QOL and helps dogs with CHF feel better.3
VETMEDIN is now available in 4 dosage sizes to fit each dog's individual needs.
VETMEDIN is proven to lengthen life with few adverse events.2
Use VetMedin here
stage aHigh-risk dogs with
no structural abnormality or murmur
stage BStructural abnormality but
no clinical signs of heart failure
stage dClinical signs of heart
failure refractory to standard treatment
stage CStructural abnormality
and current or previous clinical signs
of heart failure
presCriBing inforMation enClosed
* Both the QuESt and VetSCOPE studies were completed using VEtMEDIN Capsules. In the uS, only the chewable tablets are licensed. Both the capsules and chewable tablets contain the same pharmaceutical ingredient, pimobendan, and are considered equivalent for clinical use. Bioequivalence, however, has not been shown.
† Survival was defined as the composite endpoint of cardiac death, euthanasia due to heart failure, or treatment failure. All dogs received furosemide therapy.
§ All doses provided as tablets.
dosing sizes
Now available in
4
Simon, 12O lbTwo 10 mg in morning andone 10 mg in evening§Clyde, 65 lb
10 mg in morning and half a 10 mg in evening§Lucky, 22 lb
![LAMPlRAN - repository.wima.ac.idrepository.wima.ac.id/1467/7/LAMPIRAN.pdf · d71 :=d7 * 2; d81:=d8 div 32; data2 :=d II +d21 +d31 +d41 +d51 +d61 +d71 +d81 ;end; port[ dac ]:=data2;](https://static.documents.pub/doc/80x56/5cfdd46888c9931f2f8ba0ff/lamplran-d71-d7-2-d81d8-div-32-data2-d-ii-d21-d31-d41-d51-d61.jpg)
